Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.
A spill of new data Wednesday sent oil futures slipping and sliding in opposite directions. So is Big Oil’s tank is half-full or half-empty?
On Tuesday, the overall yield on the US 10-Year Treasury Bond touched its highest intraday point, 4.699%, since last spring.